| Date Filed | Type | Description |
| 10/04/2023 |
4
| Heerma Peter (Chief Commercial Officer) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 3,091 shares
@ $8.2511, valued at
$25.5k
|
|
| 05/19/2023 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| Poole Sandra (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| COUGHLIN TIMOTHY (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| Williams Brinkley Ruth (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| Meckler Jeffrey A (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| Orwin John A (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| LYONS GARY A (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| Bruhn Suzanne Louise (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| Squarer Ron (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/12/2023 |
4
| Cline Christopher R. (CFO) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 455 shares
@ $16.59, valued at
$7.5k
|
|
| 05/12/2023 |
4
| REED ELIZABETH E (SVP, GC & Corporate Secretary) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 825 shares
@ $16.59, valued at
$13.7k
|
|
| 04/13/2023 |
4
| Cline Christopher R. (CFO) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 47 shares
@ $21.49, valued at
$1k
|
|
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/26/2023 |
4
| Calvin Sandra (SVP, Chief Accounting Officer) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 905 shares
@ $21.9044, valued at
$19.8k
Sold 192 shares
@ $21.63, valued at
$4.2k
|
|
| 01/26/2023 |
4
| ROTE WILLIAM E. (Senior Vice President, R&D) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 2,062 shares
@ $21.5, valued at
$44.3k
|
|
| 01/26/2023 |
4
| REED ELIZABETH E (SVP, GC & Corporate Secretary) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 2,062 shares
@ $21.5, valued at
$44.3k
|
|
| 01/26/2023 |
4
| Dube Eric M (CEO) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 6,442 shares
@ $21.5, valued at
$138.5k
|
|
| 01/26/2023 |
4
| Cline Christopher R. (CFO) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 852 shares
@ $21.9044, valued at
$18.7k
|
|
| 01/26/2023 |
4
| Heerma Peter (Chief Commercial Officer) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 1,550 shares
@ $21.9044, valued at
$34k
|
|
| 01/06/2023 |
4
| Dube Eric M (CEO) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 5,625 shares
@ $20.75, valued at
$116.7k
|
|
| 01/06/2023 |
4
| Inrig Jula (Chief Medical Officer) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 2,051 shares
@ $20.75, valued at
$42.6k
Sold 442 shares
@ $20.75, valued at
$9.2k
|
|
| 10/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/15/2022 |
4
| Calvin Sandra (SVP, Chief Accounting Officer) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 349 shares
@ $28, valued at
$9.8k
|
|
| 09/01/2022 |
4
| Cline Christopher R. (CFO) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 5,000 shares
@ $0
Granted 48,000 options to buy
@ $28.06, valued at
$1.3M
Granted 9,840 options to buy
@ $0 |
|
| 09/01/2022 |
3
| Cline Christopher R. (CFO) has filed a Form 3 on Travere Therapeutics, Inc. |
| 05/12/2022 |
4
| ROTE WILLIAM E. (Senior Vice President, R&D) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 750 shares
@ $21.93, valued at
$16.4k
Sold 813 shares
@ $21.5163, valued at
$17.5k
|
|
| 05/12/2022 |
4
| REED ELIZABETH E (SVP, GC & Corporate Secretary) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 900 shares
@ $21.51, valued at
$19.4k
Sold 1,050 shares
@ $21.509, valued at
$22.6k
|
|
|